APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine Contract Manufacturing

Compare research editions
View pricing & licenses

Selected research

Industry Research

Human Vaccine Contract Manufacturing Industry Research Report 2026

Report ID 17415816052 May 2026143 pages

Choose your research edition.

Industry ResearchHuman Vaccine Contract Manufacturing Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Human Vaccine Contract Manufacturing market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Human Vaccine Contract Manufacturing market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human Vaccine Contract Manufacturing market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human Vaccine Contract Manufacturing market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human Vaccine Contract Manufacturing include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc. and PRA Health Sciences, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Human Vaccine Contract Manufacturing market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Vaccine Contract Manufacturing.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Human Vaccine Contract Manufacturing Market by Company

Lonza

Fujifilm Diosynth Biotechnologies U.S.A., Inc.

Ajinomoto Althea, Inc.

Merck KgaA

Cytovance Biologics

Catalent, Inc.

IDT Biologika GmbH

Albany Molecular Research, Inc.

PRA Health Sciences

ICON plc.

Pharmaceutical Product Development, LLC

Cobra Bio

Paragon Bioservices, Inc.

Emergent BioSolutions Inc.

CSL Limited

BioNTech SE

Wuxi Biologics

Samsung Biologics

Boehringer Ingelheim

Novavax, Inc.

Human Vaccine Contract Manufacturing Segment by Type

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Human Vaccine Contract Manufacturing Segment by Application

Downstream

Upstream

Human Vaccine Contract Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine Contract Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Human Vaccine Contract Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2021-2026) Table 7. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Human Vaccine Contract Manufacturing Revenue Market Share by Type (2027-2032) Table 9. Global Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2021-2026) Table 11. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Human Vaccine Contract Manufacturing Revenue Market Share by Application (2027-2032) Table 13. Global Human Vaccine Contract Manufacturing Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Human Vaccine Contract Manufacturing Market Share by Region (2021-2026) Table 16. Global Human Vaccine Contract Manufacturing Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Human Vaccine Contract Manufacturing Market Share by Region (2027-2032) Table 18. Human Vaccine Contract Manufacturing Industry Trends Table 19. Human Vaccine Contract Manufacturing Industry Drivers Table 20. Human Vaccine Contract Manufacturing Industry Opportunities and Challenges Table 21. Human Vaccine Contract Manufacturing Market Restraints Table 22. Global Top Human Vaccine Contract Manufacturing Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2021-2026) Table 24. Global Human Vaccine Contract Manufacturing Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Human Vaccine Contract Manufacturing, Headquarters and Area Served Table 26. Global Human Vaccine Contract Manufacturing Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Human Vaccine Contract Manufacturing by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Human Vaccine Contract Manufacturing Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2027-2032) & (US$ Million) Table 45. Lonza Company Information Table 46. Lonza Business Overview Table 47. Lonza Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 48. Lonza Human Vaccine Contract Manufacturing Product Portfolio Table 49. Lonza Recent Developments Table 50. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information Table 51. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview Table 52. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 53. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 54. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments Table 55. Ajinomoto Althea, Inc. Company Information Table 56. Ajinomoto Althea, Inc. Business Overview Table 57. Ajinomoto Althea, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 58. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 59. Ajinomoto Althea, Inc. Recent Developments Table 60. Merck KgaA Company Information Table 61. Merck KgaA Business Overview Table 62. Merck KgaA Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 63. Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio Table 64. Merck KgaA Recent Developments Table 65. Cytovance Biologics Company Information Table 66. Cytovance Biologics Business Overview Table 67. Cytovance Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 68. Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 69. Cytovance Biologics Recent Developments Table 70. Catalent, Inc. Company Information Table 71. Catalent, Inc. Business Overview Table 72. Catalent, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 73. Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 74. Catalent, Inc. Recent Developments Table 75. IDT Biologika GmbH Company Information Table 76. IDT Biologika GmbH Business Overview Table 77. IDT Biologika GmbH Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 78. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio Table 79. IDT Biologika GmbH Recent Developments Table 80. Albany Molecular Research, Inc. Company Information Table 81. Albany Molecular Research, Inc. Business Overview Table 82. Albany Molecular Research, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 83. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 84. Albany Molecular Research, Inc. Recent Developments Table 85. PRA Health Sciences Company Information Table 86. PRA Health Sciences Business Overview Table 87. PRA Health Sciences Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 88. PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio Table 89. PRA Health Sciences Recent Developments Table 90. ICON plc. Company Information Table 91. ICON plc. Business Overview Table 92. ICON plc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 93. ICON plc. Human Vaccine Contract Manufacturing Product Portfolio Table 94. ICON plc. Recent Developments Table 95. Pharmaceutical Product Development, LLC Company Information Table 96. Pharmaceutical Product Development, LLC Business Overview Table 97. Pharmaceutical Product Development, LLC Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 98. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio Table 99. Pharmaceutical Product Development, LLC Recent Developments Table 100. Cobra Bio Company Information Table 101. Cobra Bio Business Overview Table 102. Cobra Bio Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 103. Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio Table 104. Cobra Bio Recent Developments Table 105. Paragon Bioservices, Inc. Company Information Table 106. Paragon Bioservices, Inc. Business Overview Table 107. Paragon Bioservices, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 108. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 109. Paragon Bioservices, Inc. Recent Developments Table 110. Emergent BioSolutions Inc. Company Information Table 111. Emergent BioSolutions Inc. Business Overview Table 112. Emergent BioSolutions Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 113. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 114. Emergent BioSolutions Inc. Recent Developments Table 115. CSL Limited Company Information Table 116. CSL Limited Business Overview Table 117. CSL Limited Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 118. CSL Limited Human Vaccine Contract Manufacturing Product Portfolio Table 119. CSL Limited Recent Developments Table 120. BioNTech SE Company Information Table 121. BioNTech SE Business Overview Table 122. BioNTech SE Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 123. BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio Table 124. BioNTech SE Recent Developments Table 125. Wuxi Biologics Company Information Table 126. Wuxi Biologics Business Overview Table 127. Wuxi Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 128. Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 129. Wuxi Biologics Recent Developments Table 130. Samsung Biologics Company Information Table 131. Samsung Biologics Business Overview Table 132. Samsung Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 133. Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 134. Samsung Biologics Recent Developments Table 135. Boehringer Ingelheim Company Information Table 136. Boehringer Ingelheim Business Overview Table 137. Boehringer Ingelheim Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 138. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio Table 139. Boehringer Ingelheim Recent Developments Table 140. Novavax, Inc. Company Information Table 141. Novavax, Inc. Business Overview Table 142. Novavax, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026) & (US$ Million) Table 143. Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 144. Novavax, Inc. Recent Developments Table 145. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Human Vaccine Contract Manufacturing Product Image Figure 5. Global Human Vaccine Contract Manufacturing Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Human Vaccine Contract Manufacturing Market Share by Type: 2025 VS 2032 Figure 7. Attenuated Product Figure 8. Inactivated Product Figure 9. Subunit-based Product Figure 10. Toxoid-based Product Figure 11. DNA-based Product Figure 12. Global Human Vaccine Contract Manufacturing Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Human Vaccine Contract Manufacturing Market Share by Application: 2025 VS 2032 Figure 14. Downstream Product Figure 15. Upstream Product Figure 16. Global Human Vaccine Contract Manufacturing Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 17. Global Human Vaccine Contract Manufacturing Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Human Vaccine Contract Manufacturing Market Share by Region: 2025 VS 2032 Figure 19. Global Human Vaccine Contract Manufacturing Market Share by Players in 2025 Figure 20. Global Human Vaccine Contract Manufacturing Manufacturers Established Date Figure 21. Global Top 5 and 10 Human Vaccine Contract Manufacturing Players Market Share by Revenue in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. North America Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 25. United States Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 26. Canada Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Mexico Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 28. Europe Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 30. Germany Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. France Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. U.K. Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Italy Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Spain Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Russia Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Netherlands Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Nordic Countries Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 40. China Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Japan Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. South Korea Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 43. India Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. India Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 45. Australia Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. China Taiwan Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. Southeast Asia Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 48. South America Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. South America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 50. Brazil Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Argentina Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Chile Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Colombia Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Peru Human Vaccine Contract Manufacturing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Lonza Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 56. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 57. Ajinomoto Althea, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 58. Merck KgaA Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 59. Cytovance Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 60. Catalent, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 61. IDT Biologika GmbH Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 62. Albany Molecular Research, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 63. PRA Health Sciences Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 64. ICON plc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 65. Pharmaceutical Product Development, LLC Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 66. Cobra Bio Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 67. Paragon Bioservices, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 68. Emergent BioSolutions Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 69. CSL Limited Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 70. BioNTech SE Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 71. Wuxi Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 72. Samsung Biologics Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 73. Boehringer Ingelheim Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026) Figure 74. Novavax, Inc. Revenue Growth Rate in Human Vaccine Contract Manufacturing Business (2021-2026)

Scope & coverage.

Types
  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based
Applications
  • Downstream
  • Upstream
Companies covered
  • Lonza
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • BioNTech SE
  • Wuxi Biologics
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novavax, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Human Vaccine Contract Manufacturing by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Attenuated
  5. 2.2.3 Inactivated
  6. 2.2.4 Subunit-based
  7. 2.2.5 Toxoid-based
  8. 2.2.6 DNA-based
  9. 2.3 Human Vaccine Contract Manufacturing by Application
  10. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  11. 2.3.2 Downstream
  12. 2.3.3 Upstream
  13. 2.4 Assumptions and Limitations
3 Human Vaccine Contract Manufacturing Breakdown Data by Type
  1. 3.1 Global Human Vaccine Contract Manufacturing Historic Market Size by Type (2021-2026)
  2. 3.2 Global Human Vaccine Contract Manufacturing Forecasted Market Size by Type (2027-2032)
4 Human Vaccine Contract Manufacturing Breakdown Data by Application
  1. 4.1 Global Human Vaccine Contract Manufacturing Historic Market Size by Application (2021-2026)
  2. 4.2 Global Human Vaccine Contract Manufacturing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Human Vaccine Contract Manufacturing Market Perspective (2021-2032)
  2. 5.2 Global Human Vaccine Contract Manufacturing Growth Trends by Region
  3. 5.2.1 Global Human Vaccine Contract Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Human Vaccine Contract Manufacturing Historic Market Size by Region (2021-2026)
  5. 5.2.3 Human Vaccine Contract Manufacturing Forecasted Market Size by Region (2027-2032)
  6. 5.3 Human Vaccine Contract Manufacturing Market Dynamics
  7. 5.3.1 Human Vaccine Contract Manufacturing Industry Trends
  8. 5.3.2 Human Vaccine Contract Manufacturing Market Drivers
  9. 5.3.3 Human Vaccine Contract Manufacturing Market Challenges
  10. 5.3.4 Human Vaccine Contract Manufacturing Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Human Vaccine Contract Manufacturing Players by Revenue
  2. 6.1.1 Global Top Human Vaccine Contract Manufacturing Players by Revenue (2021-2026)
  3. 6.1.2 Global Human Vaccine Contract Manufacturing Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Human Vaccine Contract Manufacturing Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Human Vaccine Contract Manufacturing Head Office and Area Served
  6. 6.4 Global Human Vaccine Contract Manufacturing Players, Product Type & Application
  7. 6.5 Global Human Vaccine Contract Manufacturing Manufacturers Established Date
  8. 6.6 Global Human Vaccine Contract Manufacturing Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 7.2 North America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  4. 7.4 North America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 8.2 Europe Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  4. 8.4 Europe Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 9.2 Asia-Pacific Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 10.2 South America Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  4. 10.4 South America Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Human Vaccine Contract Manufacturing Market Size (2021-2032)
  2. 11.2 Middle East & Africa Human Vaccine Contract Manufacturing Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Lonza
  2. 12.1.1 Lonza Company Information
  3. 12.1.2 Lonza Business Overview
  4. 12.1.3 Lonza Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  5. 12.1.4 Lonza Human Vaccine Contract Manufacturing Product Portfolio
  6. 12.1.5 Lonza Recent Developments
  7. 12.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  8. 12.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information
  9. 12.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
  10. 12.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  11. 12.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio
  12. 12.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
  13. 12.3 Ajinomoto Althea, Inc.
  14. 12.3.1 Ajinomoto Althea, Inc. Company Information
  15. 12.3.2 Ajinomoto Althea, Inc. Business Overview
  16. 12.3.3 Ajinomoto Althea, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  17. 12.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  18. 12.3.5 Ajinomoto Althea, Inc. Recent Developments
  19. 12.4 Merck KgaA
  20. 12.4.1 Merck KgaA Company Information
  21. 12.4.2 Merck KgaA Business Overview
  22. 12.4.3 Merck KgaA Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  23. 12.4.4 Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio
  24. 12.4.5 Merck KgaA Recent Developments
  25. 12.5 Cytovance Biologics
  26. 12.5.1 Cytovance Biologics Company Information
  27. 12.5.2 Cytovance Biologics Business Overview
  28. 12.5.3 Cytovance Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  29. 12.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio
  30. 12.5.5 Cytovance Biologics Recent Developments
  31. 12.6 Catalent, Inc.
  32. 12.6.1 Catalent, Inc. Company Information
  33. 12.6.2 Catalent, Inc. Business Overview
  34. 12.6.3 Catalent, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  35. 12.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  36. 12.6.5 Catalent, Inc. Recent Developments
  37. 12.7 IDT Biologika GmbH
  38. 12.7.1 IDT Biologika GmbH Company Information
  39. 12.7.2 IDT Biologika GmbH Business Overview
  40. 12.7.3 IDT Biologika GmbH Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  41. 12.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio
  42. 12.7.5 IDT Biologika GmbH Recent Developments
  43. 12.8 Albany Molecular Research, Inc.
  44. 12.8.1 Albany Molecular Research, Inc. Company Information
  45. 12.8.2 Albany Molecular Research, Inc. Business Overview
  46. 12.8.3 Albany Molecular Research, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  47. 12.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  48. 12.8.5 Albany Molecular Research, Inc. Recent Developments
  49. 12.9 PRA Health Sciences
  50. 12.9.1 PRA Health Sciences Company Information
  51. 12.9.2 PRA Health Sciences Business Overview
  52. 12.9.3 PRA Health Sciences Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  53. 12.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio
  54. 12.9.5 PRA Health Sciences Recent Developments
  55. 12.10 ICON plc.
  56. 12.10.1 ICON plc. Company Information
  57. 12.10.2 ICON plc. Business Overview
  58. 12.10.3 ICON plc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  59. 12.10.4 ICON plc. Human Vaccine Contract Manufacturing Product Portfolio
  60. 12.10.5 ICON plc. Recent Developments
  61. 12.11 Pharmaceutical Product Development, LLC
  62. 12.11.1 Pharmaceutical Product Development, LLC Company Information
  63. 12.11.2 Pharmaceutical Product Development, LLC Business Overview
  64. 12.11.3 Pharmaceutical Product Development, LLC Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  65. 12.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio
  66. 12.11.5 Pharmaceutical Product Development, LLC Recent Developments
  67. 12.12 Cobra Bio
  68. 12.12.1 Cobra Bio Company Information
  69. 12.12.2 Cobra Bio Business Overview
  70. 12.12.3 Cobra Bio Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  71. 12.12.4 Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio
  72. 12.12.5 Cobra Bio Recent Developments
  73. 12.13 Paragon Bioservices, Inc.
  74. 12.13.1 Paragon Bioservices, Inc. Company Information
  75. 12.13.2 Paragon Bioservices, Inc. Business Overview
  76. 12.13.3 Paragon Bioservices, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  77. 12.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  78. 12.13.5 Paragon Bioservices, Inc. Recent Developments
  79. 12.14 Emergent BioSolutions Inc.
  80. 12.14.1 Emergent BioSolutions Inc. Company Information
  81. 12.14.2 Emergent BioSolutions Inc. Business Overview
  82. 12.14.3 Emergent BioSolutions Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  83. 12.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio
  84. 12.14.5 Emergent BioSolutions Inc. Recent Developments
  85. 12.15 CSL Limited
  86. 12.15.1 CSL Limited Company Information
  87. 12.15.2 CSL Limited Business Overview
  88. 12.15.3 CSL Limited Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  89. 12.15.4 CSL Limited Human Vaccine Contract Manufacturing Product Portfolio
  90. 12.15.5 CSL Limited Recent Developments
  91. 12.16 BioNTech SE
  92. 12.16.1 BioNTech SE Company Information
  93. 12.16.2 BioNTech SE Business Overview
  94. 12.16.3 BioNTech SE Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  95. 12.16.4 BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio
  96. 12.16.5 BioNTech SE Recent Developments
  97. 12.17 Wuxi Biologics
  98. 12.17.1 Wuxi Biologics Company Information
  99. 12.17.2 Wuxi Biologics Business Overview
  100. 12.17.3 Wuxi Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  101. 12.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio
  102. 12.17.5 Wuxi Biologics Recent Developments
  103. 12.18 Samsung Biologics
  104. 12.18.1 Samsung Biologics Company Information
  105. 12.18.2 Samsung Biologics Business Overview
  106. 12.18.3 Samsung Biologics Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  107. 12.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio
  108. 12.18.5 Samsung Biologics Recent Developments
  109. 12.19 Boehringer Ingelheim
  110. 12.19.1 Boehringer Ingelheim Company Information
  111. 12.19.2 Boehringer Ingelheim Business Overview
  112. 12.19.3 Boehringer Ingelheim Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  113. 12.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio
  114. 12.19.5 Boehringer Ingelheim Recent Developments
  115. 12.20 Novavax, Inc.
  116. 12.20.1 Novavax, Inc. Company Information
  117. 12.20.2 Novavax, Inc. Business Overview
  118. 12.20.3 Novavax, Inc. Revenue in Human Vaccine Contract Manufacturing Business (2021-2026)
  119. 12.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  120. 12.20.5 Novavax, Inc. Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst